相关实验视频
Updated: May 7, 2025

04:28
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
5.2K
转移的泛癌驱动因素
Ryan Lusby1, Engin Demirdizen2, Mohammed Inayatullah2
1Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry & Biomedical Science, Queens University Belfast, Belfast, BT9 7BL, UK.
Molecular cancer
|January 3, 2025
概括
这项研究揭示了一个核心基因特征驱动多种癌症类型的癌症转移. SP1和KLF5转录因子被确定为关键调节剂,在WNT信号抑制剂中发现了潜在的治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 转移是癌症死亡率的主要驱动因素,但潜在的基因调节程序尚未完全理解.
- 识别不同癌症的共同机制对于开发有效的抗转移疗法至关重要.
研究的目的:
- 阐明控制转移的泛癌基因调节网络.
- 为了确定关键的转录因子和信号通路涉及转移性进展.
- 发现潜在的治疗策略来抑制转移.
主要方法:
- 在六种癌症类型中对200多名转移性和非转移性瘤患者的单细胞转录组分析.
- 转录因子网络的剖析和功能干扰研究.
- 在体内和体内对SP1的功能丧失实验.
- 药物重用分析专注于FDA批准的药物.
主要成果:
- 确定了转移的预后核心基因签名,为细胞动态和基因调节网络提供了洞察力.
- SP1被确定为转移的驱动因素,促进癌细胞生存,入侵和殖民.
- KLF5作为转移的抑制剂.
- 瘤细胞与微环境之间的WNT信号通信在转移期间增加,由SP1.1驱动.
- 美国食品和药物管理局批准的药物,包括WNT信号抑制剂,显示出抗转移潜力.
结论:
- 一个保存的基因调节程序是多种癌症类型转移的基础.
- SP1和KLF5是转移的关键调节者,具有治疗点.
- 准WNT信号通路为抗转移治疗提供了一个有希望的策略.
相关概念视频
Metastasis
5.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.4K
Cancer Cell Migration through Invadopodia
2.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.2K
Cancers Originate from Somatic Mutations in a Single Cell
11.3K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.3K
Mitogens and the Cell Cycle
6.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
Adaptive Mechanisms in Cancer Cells
5.5K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.5K
Tumor Progression
6.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.0K

